GH Research PLC (NASDAQ:GHRS) Receives $40.13 Consensus Price Target from Analysts

GH Research PLC (NASDAQ:GHRS) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $40.1250.

Several equities analysts have weighed in on the company. Citizens Jmp increased their price objective on GH Research from $39.00 to $42.00 and gave the company a “market outperform” rating in a report on Friday, March 6th. Wolfe Research set a $39.00 price target on GH Research in a report on Tuesday, January 6th. Canaccord Genuity Group raised their price target on GH Research from $35.00 to $39.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. HC Wainwright raised their price target on GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Royal Bank Of Canada raised their price target on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd.

Institutional Investors Weigh In On GH Research

Several large investors have recently added to or reduced their stakes in GHRS. JPMorgan Chase & Co. purchased a new stake in GH Research during the second quarter valued at about $79,000. BNP Paribas Financial Markets raised its position in GH Research by 165.4% during the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares in the last quarter. Osaic Holdings Inc. raised its position in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares in the last quarter. AdvisorShares Investments LLC raised its position in GH Research by 41.1% during the third quarter. AdvisorShares Investments LLC now owns 53,991 shares of the company’s stock valued at $772,000 after purchasing an additional 15,735 shares in the last quarter. Finally, CenterBook Partners LP purchased a new stake in GH Research during the third quarter valued at about $2,376,000. Institutional investors own 56.90% of the company’s stock.

GH Research Stock Up 3.9%

Shares of GH Research stock opened at $16.34 on Friday. The company has a market cap of $1.01 billion, a PE ratio of -20.42 and a beta of 1.00. GH Research has a 52 week low of $8.51 and a 52 week high of $19.51. The business has a 50 day moving average price of $15.03 and a 200-day moving average price of $14.51.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. As a group, research analysts anticipate that GH Research will post -0.8 EPS for the current year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.